Bioxcel therapeutics announces positive fda pre-snda meeting comments for snda submission for bxcl501 in agitation associated with bipolar disorders or schizophrenia

Achieved alignment with the fda on snda package to expand the igalmi label for the at-home (outpatient) setting snda submission on track for q1 2026 new haven, conn., aug. 18, 2025 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received positive pre-snda meeting responses from the u.s. food and drug administration (fda).
BTAI Ratings Summary
BTAI Quant Ranking